Smartleaf Asset Management’s Aktis Oncology AKTS Stock Holding History

Smartleaf Asset Management’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.6K	Buy	+81	New	+$1.97K	﹤0.01%	3100

Other funds holding AKTS

Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Merck & Co Rahway, New Jersey $820M AUM 395.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $116B AUM 33.19% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Smartleaf Asset Management's AKTS Position: Q3 2026 in Review

Smartleaf Asset Management opened a new position in Aktis Oncology (AKTS) in Q3 2026: 81 shares worth $1.6K. The stake represents ﹤0.01% of the portfolio and ranks #3100 among its holdings.

76 funds tracked by Wall St. Rank hold AKTS as of Q3 2026.

Smartleaf Asset Management held 81 shares of Aktis Oncology worth $1.6K as of Q3 2026.
Aktis Oncology was a new Smartleaf Asset Management position in Q3 2026.
Aktis Oncology made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3100 holding.
76 funds tracked by Wall St. Rank held Aktis Oncology as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.